Mucormycosis
19
4
6
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 19 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (19)
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.
Biomarkers for Invasive Mucormycosis
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
Isavuconazole in Critically Ill Patients: Efficacy and Safety
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
Rehabilitation With an Obturator in Maxillary Defects
Mucorales PCR Screening in At-risk Hematology Patients
COVID-19 and Rhino-orbital Mucormycosis
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Mucormycosis in COVID-19
Mucormycosis in ICU
Evaluation of Using 3D Printed PEEK Facial Implants in Repairing Maxillofacial Deformities
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis